All In Biotech

Drug Trial Radar · NCT03747575

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

65

Actual

Start

Feb 6, 2019

Primary completion

Mar 11, 2020

Study completion May 5, 2020

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.

Conditions

  • Atopic Dermatitis

Interventions

  • MSTT1041ADrug

    Participants will receive subcutaneous (SC) MSTT1041A

  • PlaceboDrug

    Participants will receive SC placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change of Total Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline, Week 16

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Alabama Allergy & Asthma

    Birmingham, Alabama

  • California Allergy and Asthma Medical Group - CRN

    Los Angeles, California

  • Jonathan Corren MD, Inc.

    Los Angeles, California

  • Asthma & Allergy; Associates, P.C.

    Colorado Springs, Colorado

  • South Coast Research Center, Inc.

    Miami, Florida

  • Harmony Clinical Research, Inc

    North Miami Beach, Florida

  • GCP Global Clinical Professionals

    St. Petersburg, Florida

  • Forward Clinical Trials

    Tampa, Florida

  • Florida Pulmonary Research Institute, LLC

    Winter Park, Florida

  • Midwest Sinus Allergy and Asthma - CRN

    Normal, Illinois

  • Dermatology Specialists Research, LLC

    Louisville, Kentucky

  • Clinical Research Consortium Nevada

    Las Vegas, Nevada

  • Skin Laser and Surgery Specialists of New York and New Jersey LLC - Interspond - PPDS

    Hackensack, New Jersey

  • Vital Prospects Clinical Research Institute PC - CRN

    Tulsa, Oklahoma

  • Center for Clinical Studies

    Houston, Texas

  • Universitatsklinikum Munster

    Münster, Germany

  • Centrum Medyczne ALL-MED

    Krakow, Poland

  • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi

    Lodz, Poland

  • Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina; Klinika Dermatologii

    Rzeszów, Poland

  • Laser Clinic

    Szczecin, Poland

  • Wro Medica

    Wroc?aw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.